Focus
Molecular Diagnostics Investors: Angels and VC Firms
The RaiseHunt database lists 57 Molecular Diagnostics investors: 33 angel investors and 24 people at 4 firms. Most list Seed and Series A among their stages; the largest hubs are San Francisco, Shanghai and Hong Kong.
Strongest in San Francisco, Shanghai and Hong Kong
- 57
- Molecular Diagnostics investors
- 33
- Angel investors
- 24
- People at VC/PE firms
- 4
- Firms tagged
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
57 Molecular Diagnostics investors
Showing 1-20
| Investor | Location | Type | Markets | Contact | Actions |
|---|---|---|---|---|---|
Reed Sturtevant Managing Director at Project 11 | Lexington, United States | Angel | EnergyFinTech | View profile | |
Cyriac Roeding Investor at Roeding Ventures | Portola Valley, United States | AngelOperator angel | AIHealthcare | View profile | |
Naveen Jain angel investor and operator angel | Bellevue, United States | AngelOperator angel | AIConsumer | View profile | |
Ameera Shah angel investor | Mumbai, India | Angel | AIHealthcare | View profile | |
Ryan Fukushima angel investor and operator angel | Chicago, United States | AngelOperator angel | AIHealthcare | View profile | |
Art Pappas Founder at Pappas Capital | Durham, United States | Angel | Healthcare | View profile | |
XiangQian XQ Lin CEO at Esco | Singapore | AngelOperator angel | Healthcare | View profile | |
Akash Gehani angel investor and operator angel | Bengaluru, India | AngelOperator angel | ConsumerHardware | View profile | |
Noah Zimmerman angel investor and operator angel | San Francisco, United States | AngelOperator angel | AIHealthcare | View profile | |
Jeanette Welsh Investor at Telegraph Hill Capital | San Francisco, United States | Private equityVenture capital | AICommerce | View profile | |
Alex Herzick Partner at Telegraph Hill Capital | Durham, United States | Private equityVenture capital | AICommerce | View profile | |
Tom Raffin General Partner/Co-Founder at Telegraph Hill Capital | San Francisco, United States | Private equityVenture capital | AICommerce | View profile | |
Rishi Kacker angel investor | San Francisco, United States | Angel | Healthcare | View profile | |
Lizzie Ngo angel investor and operator angel | Boston, United States | AngelOperator angel | Healthcare | View profile | |
Norbert Bischofberger angel investor and operator angel | San Mateo, United States | AngelOperator angel | Healthcare | View profile | |
Rakesh Somani angel investor | Surat, India | Angel | ConsumerFood | View profile | |
Fred Craves Owner at Bay City Capital | San Francisco, United States | Private equityVenture capital | Healthcare | View profile | |
Soenke Weissenborn angel investor | Aachen, Germany | Angel | Healthcare | View profile | |
NJ Nickhil Jakatdar First Investor at Genies | Los Altos, United States | AngelOperator angel | ConsumerHealthcare | View profile | |
RM Roger Moody Chief Executive Officer at Biocartis | Chicago, United States | Angel | Healthcare | View profile |
Frequently asked questions
How many Molecular Diagnostics investors are on RaiseHunt?
RaiseHunt currently lists 57 Molecular Diagnostics investors.
Are Molecular Diagnostics investors angels or funds?
Both. 33 are angel investors putting in their own money, and 24 are people making investment decisions at 4 firms.
Where are most Molecular Diagnostics investors based?
The largest concentrations are in San Francisco, Shanghai and Hong Kong.
What stage do Molecular Diagnostics investors invest at?
Most list Seed and Series A among the rounds they take part in.
How do I contact Molecular Diagnostics investors?
Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.
Is the list of Molecular Diagnostics investors free to browse?
Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.
Do Molecular Diagnostics investors only back Molecular Diagnostics companies?
No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.
Should I raise from one investor or several?
Several, in almost every case. A single backer concentrates the risk of the round collapsing if that one conversation goes cold, and a group brings more introductions later. Rounds are usually assembled from a lead plus others who follow.
How do I follow up without being annoying?
Follow up with new information rather than a reminder. A short note saying what changed since you last wrote gives the reader a reason to reply, where "just checking in" gives them none. Two or three of those, spaced out, is normal and expected.
What if no Molecular Diagnostics investor replies?
Usually the list was too short or too loosely matched, not that the company is unfundable. Widen it, tighten who you are writing to, and rewrite the first two lines of the message. Those lines decide whether anything below them gets read.
What is the difference between an angel investor and a VC fund?
An angel invests their own money and can decide alone, which usually makes the process shorter. A fund invests money it raised from other people, so it answers to those backers and normally runs a longer diligence process before it commits. Founders often raise from angels first and bring in a fund once there is more to show.
How many Molecular Diagnostics investors should I contact?
Far more than feels comfortable. Response rates on cold outreach are low even when the fit is good, so a list of a handful of perfect names tends to stall. Build a long list, sort it by how well each one matches what you are building, and work down it in batches rather than sending everything at once.
Data: RaiseHunt investor dataset · Snapshot 27 August 2026 · How this data is built · Report a correction or request removal
